UTHR Stock Risk & Deep Value Analysis
United Therapeutics Corp
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About UTHR Stock
We analyzed United Therapeutics Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran UTHR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is UTHR Stock?
Overall Risk
Aggressive
Financial Risk
Low
Market Risk
Low
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for UTHR?
- ⚠
Failure or significant delays in key xenotransplantation clinical trials
- ⚠
Adverse regulatory decisions or prolonged approval processes for xenotransplantation
- ⚠
Increased competitive pressure or patent expiry impacts on existing PAH franchise
- ⚠
Unfavorable Q1 2026 earnings report or reduced forward guidance
Unlock UTHR Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does United Therapeutics Corp (UTHR) Do?
Market Cap
$22.13B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Visit United Therapeutics Corp WebsiteIs UTHR Stock Undervalued?
Unlock the full AI analysis for UTHR
Get the complete DVR score, risk analysis, and more
Is UTHR Financially Healthy?
P/E Ratio
18.56
Does UTHR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
While existing PAH drug patents will eventually expire, United Therapeutics' aggressive investment in xenotransplantation is building a new, potentially vast moat based on novel technology, regulatory approvals, and manufacturing scale that could endure for decades, effectively replacing or augmenting its current moat.
Moat Erosion Risks
- •Patent expiration and generic competition for its existing PAH drug portfolio.
- •Failure or significant setbacks in commercializing xenotransplantation, leaving the company reliant on its maturing core business.
- •Emergence of competing organ regeneration technologies or alternative treatments that bypass xenotransplantation.
UTHR Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive UTHR Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated late April / early May 2026)
- •Updates on PAH pipeline expansions or new indication approvals
Medium-Term (6-18 months)
- •Further clinical progress updates for xenotransplantation programs (e.g., pig kidney, heart transplantation), possibly mid-stage data readouts
- •Potential strategic partnerships for specific aspects of xenotransplantation technology or manufacturing
Long-Term (18+ months)
- •Phase 3 clinical trial initiation and data for xenotransplantation programs
- •Initial commercial launch of a xenotransplantation product, signaling market creation
- •Disruption of traditional organ donation and transplant market through scalable organ manufacturing
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for UTHR?
- ✓
Significant positive clinical trial data or accelerated regulatory pathways for xenotransplantation programs.
- ✓
Sustained growth and market share expansion in its core PAH franchise, maintaining robust cash flow.
- ✓
Clear progress in scaling xenotransplantation manufacturing capabilities and reducing costs.
Bull Case Analysis
See what could go right with Premium
Compare UTHR to Similar Stocks
See how United Therapeutics Corp stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for UTHR (United Therapeutics Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
